<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067946</url>
  </required_header>
  <id_info>
    <org_study_id>GX-19N-HV-004</org_study_id>
    <nct_id>NCT05067946</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines</brief_title>
  <official_title>A Phase 2/3, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GX-19N, A DNA Vaccine, in Healthy Individuals Who Have Received One of the COVID-19 Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PT Kalbe Farma TBK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and immunogenicity of GX-19N in&#xD;
      healthy individuals who have received one of COVID-19 vaccine authorized for emergency use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First occurrence of COVID-19 at least 14 days after the second vaccination</measure>
    <time_frame>Up to 1 year after first vaccination</time_frame>
    <description>Symptomatic, virologically confirmed COVID-19 as described in the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of severe solicited adverse events (AEs)</measure>
    <time_frame>Up to 7 days after each vaccination</time_frame>
    <description>Percentage of subjects reporting grade 3 or higher AEs after each vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs and Serious AEs (SAEs) after each vaccination</measure>
    <time_frame>Up to 1 month after each vaccination</time_frame>
    <description>Percentage of subjects reporting AEs and SAEs after each vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of SAE, and Adverse events of special interest (AESIs), which relevant to COVID-19 including possible vaccine-enhanced disease</measure>
    <time_frame>Up to 1 year after first vaccination</time_frame>
    <description>SAE and AESIs reported in all subjects at any time after the first vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First occurrence of severe COVID-19 at least 14 days after the second vaccination</measure>
    <time_frame>Up to 1 year after first vaccination</time_frame>
    <description>Symptomatic, virologically confirmed severe COVID-19 as described in the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated immune responses after vaccination</measure>
    <time_frame>Up to 1 year after first vaccination</time_frame>
    <description>Antigen-specific T cell response in a subset of Phase 2/3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody responses after vaccination</measure>
    <time_frame>Up to 1 year after first vaccination</time_frame>
    <description>Analysis of binding antibodies and neutralizing antibodies in a subset of Phase 2/3</description>
  </secondary_outcome>
  <other_outcome>
    <measure>First occurrence of COVID-19 at least 14 days after the first vaccination</measure>
    <time_frame>Up to 1 year after first vaccination</time_frame>
    <description>Symptomatic, virologically confirmed COVID-19 as described in the study</description>
  </other_outcome>
  <other_outcome>
    <measure>First occurrence of asymptomatic, virologically confirmed COVID-19 at least 14 days after the last vaccination in subjects</measure>
    <time_frame>Up to 1 year after first vaccination</time_frame>
    <description>Without symptom, but virologically confirmed COVID-19 as described in the study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14000</enrollment>
  <condition>SARS-CoV2 Infection</condition>
  <arm_group>
    <arm_group_label>GX-19N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-19N will be intramusculary administered via EP on day 1 and day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be intramusculary administered via EP on day 1 and day 29</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GX-19N</intervention_name>
    <description>DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen</description>
    <arm_group_label>GX-19N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>GX-19N formulation buffer</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult males or females aged 18 years and above at the time of consent&#xD;
&#xD;
          2. Healthy subjects in normal medical condition as determined by medical history,&#xD;
             physical examination, and investigator's discretion&#xD;
&#xD;
          3. Have previously received homologous full-dose of COVID-19 vaccine authorized for&#xD;
             emergency use, and at least 3 months post second vaccination prior to Day 1&#xD;
&#xD;
          4. Negative results for SARS-COV-2 rapid antigen test at the screening period&#xD;
&#xD;
          5. Able to comply with all study procedures and requirements&#xD;
&#xD;
          6. Agree for blood and nasal swab samples could be collected throughout the study period,&#xD;
             including surveillance visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to follow clinical and follow-up procedures&#xD;
&#xD;
          2. Acute fever with temperature above 38℃, coughing, breathing difficulty, chills, muscle&#xD;
             ache, headache, sore throat, loss of smell, or loss of taste within 72 hours prior to&#xD;
             the vaccination&#xD;
&#xD;
          3. History of SARS-CoV-2 infection or have experienced prior administration of an&#xD;
             investigational coronavirus (SARS-CoV, MERS-CoV) vaccine&#xD;
&#xD;
          4. History of a malignant disease within the past 5 years&#xD;
&#xD;
          5. Immune dysfunction, including immunodeficiency disorder, or family history of such&#xD;
             conditions (Except stable/well-controlled HIV-positive participants)&#xD;
&#xD;
          6. Have received immunoglobulin or blood-derived products within 3 months prior to the&#xD;
             vaccination or are scheduled to receive them during the study period&#xD;
&#xD;
          7. Have been dependent on antipsychotic drugs and narcotic analgesics within 6 months&#xD;
             prior to the vaccination&#xD;
&#xD;
          8. History or are suspected of alcohol or drug dependency&#xD;
&#xD;
          9. History of hypersensitivity or allergic reactions including anaphylaxis&#xD;
&#xD;
         10. A current or history of clinically significant chronic cardiovascular, endocrine,&#xD;
             gastrointestinal, hepatic (including hepatitis B and C), renal, neurological,&#xD;
             respiratory, psychiatric or other medical disorders not excluded by other exclusion&#xD;
             criteria, that are assessed by the investigator&#xD;
&#xD;
         11. Hemophiliacs or people using anticoagulants who are at a risk of serious bleeding from&#xD;
             IM injection&#xD;
&#xD;
         12. Have received or plans to receive other vaccination(s) within 28 days prior to or&#xD;
             during study duration (except for influenza vaccine which is not allowed within 14&#xD;
             days before, or 4 weeks after final dose of IP)&#xD;
&#xD;
         13. Have taken an immunosuppressant or immune-modifying drug within 3 months prior to the&#xD;
             vaccination; chronic administration (defined as more than 14 continuous days) of&#xD;
             immunosuppressant medication within the past 3 months, except topical steroids or&#xD;
             short-term oral steroids (course lasting ≤ 14 days)&#xD;
&#xD;
         14. Female who are pregnant or breastfeeding; however, participation is possible if&#xD;
             breastfeeding is discontinued prior to participation in the study&#xD;
&#xD;
         15. Have received or have plans to receive other investigational drug(s) while&#xD;
             participating in another clinical study or bioequivalence study within 28 days prior&#xD;
             to vaccination&#xD;
&#xD;
         16. Not consent to the use of effective contraception at least 90 days after the last&#xD;
             vaccination&#xD;
&#xD;
         17. Lack of acceptable sites available for IM injection and EP&#xD;
&#xD;
         18. Deemed ineligible by the investigator based on other clinically significant medical or&#xD;
             psychiatric findings&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JungWon Woo, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genexine, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minkyu Heo</last_name>
    <phone>82-31-628-3340</phone>
    <email>mkheo@genexine.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

